Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.

NCT00381251 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis
Postmenopause

Interventions

DRUG: Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer